Research programme: peptides - APIM Therapeutics

Drug Profile

Research programme: peptides - APIM Therapeutics

Alternative Names: ATX 101

Latest Information Update: 31 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator APIM Therapeutics; Norwegian university of science and technology
  • Class Antineoplastics; Peptides
  • Mechanism of Action Proliferating cell nuclear antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Bladder cancer; Breast cancer; Cancer; Glioblastoma; Multiple myeloma; Prostate cancer

Most Recent Events

  • 25 May 2018 Therapim plans a first-in-man phase I trial of ATX 101 for Solid tumours (Late-stage disease) in Australia (ACTRN12618001070224p) (ACTRN12618001112257)
  • 25 May 2018 Preclinical trials in Cancer in Norway (Parenteral) before May 2018
  • 25 May 2018 Therapim files an IND application for ATX 101 with the Therapeutic Goods Administration in Australia for Solid tumours in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top